Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

News feed

Delimobil has launched car rental through its website

9/15/25 DELI

X5 introduces its own ready-to-eat quality label

9/15/25 X5

Pprosecutor's office demands to demolish the YUGK workshops in the Plastovsky district

9/15/25 UGLD

Shareholders of Yandex approved dividends

9/15/25 YDEX

Legal entity of the Nau Engine game engine is in liquidation

9/15/25 VKCO

Fix Price started buyback

9/15/25 FIXR

Ozon Pharmaceuticals has launched the Immunotresan drug on the market

9/15/25 OZPH

T-Bank launches contactless payment service for iPhone

9/15/25 T

Sk Capital received 12.76% of Softline

9/12/25 SOFL

Shareholders of Phosagro approved dividends

9/12/25 PHOR